Screening for Small-Molecule Inhibitors of Histone Methyltransferases.

Area of Science:

• Biochemistry and Medicinal Chemistry
• Epigenetics and Chemical Biology

Background:

• Histone methyltransferases (HMTs) are crucial epigenetic regulators with significant therapeutic potential.
• Developing potent and selective small-molecule inhibitors for HMTs is essential for biological research and drug discovery.
• Identifying validated chemical matter from large compound libraries is a critical first step for medicinal chemistry campaigns.

Purpose of the Study:

• To describe a robust screening and hit triage strategy for identifying validated chemical matter for HMT inhibitor development.
• To present EZH2 as a model enzyme for this screening approach.
• To introduce a cell-based assay for supporting lead identification and optimization.

Main Methods:

• Utilized a combination of biochemical and biophysical assays for primary screening and hit validation.
• Employed a rigorous hit triage process to select promising starting points.
• Incorporated a cell-based assay to assess compound activity in a biological context.

Main Results:

• Successfully identified validated chemical matter for initiating medicinal chemistry studies targeting EZH2.
• Demonstrated the utility of the described screening and triage approach.
• Showcased the applicability of a cell-based assay for lead optimization.

Conclusions:

• The presented integrated assay strategy is effective for identifying validated starting points for HMT inhibitor discovery.
• This approach provides a foundation for developing novel therapeutics targeting epigenetic dysregulation.
• The methodology is adaptable for identifying starting points for other histone methyltransferases.